苯达莫司汀联合利妥昔单抗一线治疗滤泡性淋巴瘤后利妥昔单抗维持治疗或观察的对比研究
该回顾性研究收集了640例初诊滤泡性淋巴瘤患者数据,比较苯达莫司汀联合利妥昔单抗(BR)诱导后利妥昔单抗维持治疗(MR)与观察的疗效与耐受性。研究发现,≥4周期BR后达部分缓解(PR)的患者接受MR较未维持者缓解持续时间(DOR)改善,而达完全缓解者无此获益,该结果在验证队列中得到证实。整个研究人群中BR后已知致死性不良事件率为2.5%,MR组与未维持组无显著差异。
要点
- ≥4周期BR后达PR的FL患者,接受MR较未维持者DOR改善,CR患者无此获益。
- 上述发现在验证队列中得到证实。
- 整个研究人群BR后已知致死性不良事件率为2.5%,MR组与未维持组无显著差异。
核心结论
- 在回顾性分析固有的局限性内,这些数据提示对BR诱导后达PR的FL患者,MR可延长缓解且安全性可接受。
研究设计与样本
- 回顾性收集640例初诊滤泡性淋巴瘤患者数据,比较BR诱导后利妥昔单抗维持治疗与观察的疗效和耐受性,并设验证队列。
主要发现
- ≥4周期BR后达部分缓解(PR)的患者,接受MR较未维持者缓解持续时间(DOR)改善,而达完全缓解(CR)的患者无此获益。
- 上述发现在验证队列中得到证实。
- 整个研究人群中BR后已知致死性不良事件率为2.5%,MR组与未维持组无显著差异。
局限性
- 原文指出该分析为回顾性分析,存在其固有的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit follicular lymphoma (FL) patients. The safety and efficacy of maintenance rituximab (MR) after BR induction has not been formally compared to observation for FL, resulting in disparate practice patterns. Prospective trials have shown benefit of MR after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or R-CVP (rituximab, cyclophosphamide, vincristine, prednisone), yet recent data from the GALLIUM study comparing outcomes of patients treated with chemotherapy with R or obinutuzumab (G) showed higher than anticipated fatal adverse events with BR/BG. In order to assess the efficacy and tolerability of MR after BR, we retrospectively collected data on 640 newly diagnosed patients treated with FL. We found that patients who achieved partial remission (PR) after ≥4 cycles of BR had improved duration of response (DOR) with MR vs. no maintenance, whereas those in complete remission did not. These findings were confirmed in a validation cohort. In the entire study population, the known fatal adverse event rate after BR was 2·5% and did not significantly differ in those receiving MR versus no maintenance. [Correction added on 14 January 2019, after online publication: The preceding sentence has been corrected in this current version.] Within the limitations inherent to retrospective analysis, these data suggest that FL patients with a PR to BR experience prolongation of remission with MR with an acceptable safety profile.
引用
- Hill BT, Nastoupil L, Winter AM, et al. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol. 2018. PMID: 30575016. doi:10.1111/bjh.15720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。